

## Love Actuary

### #171 - Catastrophe losses hit in excess of \$100bn for the fifth year in a row

- In this week's Love Actuary we consider how much of the burden of natural catastrophes has fallen on reinsurers in recent years. The January reinsurance renewals are only a few weeks away and we think the mainstream view is that price declines will be double digits in property catastrophe lines; not an unreasonable outcome given the supernormal levels of profitability made in 2025 which will help to bolster balance sheets for years to come. Headlines will look tough on property catastrophe lines but margins will remain extremely healthy in our view. With more strings to its bow via balance sheet optionality, we remain most positive on **Munich Re (OW, +CW)**.
- 2025 is the fifth year in a row with catastrophe claims above \$100bn.** Insured levels of catastrophe losses have been on an upward trend. Before 2021 there had only ever been 3 years in which global insured catastrophe losses had exceeded \$100bn based on data from Swiss Re. Since 2021 we have seen this level breached on an annual basis and this is likely to be the case again in 2025. We believe that the best way to think about catastrophe claims is relative to insurance industry premium and on this basis the impact is less noticeable. Catastrophe claims over 1980-2025E have been ~3% of non-life industry premiums and using the 2021-25E this ratio is 2.9%.
- Reinsurers seeing fewer claims relative to the industry.** 2021-25E have been average years for catastrophe losses relative to the size of the industry using a 1980-2025E average. But there has been a shift in who has been responsible for claims. Of the 5 years in question, it was only really 2022 which was worse than the LT average with catastrophe claims 10% higher than usual at 3.3%. The reinsurers, on average, exceeded their natural catastrophe budgets in 2021 and 2022 but have remained below their budgets since 2023.
- Price will be the main focus at the January 1 renewals but we think this only paints half the picture.** Based on our analysis, we believe that there is strong evidence that the generational change in reinsurance programme retentions at the beginning of 2023 truly reset profitability in reinsurance. Price declines are unhelpful but what is clear now is that the ~35% price increases at the beginning of 2023 materially understated the step up in reinsurance industry profitability.
- Did you know?** Did you know that it is possible to buy Santa liability insurance. One Sure Insurance offers this cover and states that professional liability insurance for Santa can act as a financial safeguard should any claims be filed against the performer by a member of the public.
- Quote of the week:** *"There is a compelling case for stronger building codes across the Northeast and mid-Atlantic, bringing standards in line with hurricane-prone states such as Florida and Louisiana. Without such measures, the protection gap will widen, leaving more people vulnerable to the catastrophic impact of these storms. This season stands as one of the starkest reminders of the risks we now face."* Sam Phibbs, Head of Catastrophe Research, MS Amlin talking about the 2025 Atlantic hurricane season.

#### European Insurance

**Kamran M Hossain** <sup>AC</sup>  
(44-20) 3493-3780  
kamran.hossain@jpmorgan.com

**Farooq Hanif**  
(44 207) 742-8091  
farooq.hanif@jpmorgan.com

**Nadia Claressa**  
(44-20) 7134-7613  
nadia.claressa@jpmorgan.com

**Bingdi Fan, CFA**  
(44-20) 7742-5336  
bingdi.fan@jpmorgan.com  
J.P. Morgan Securities plc

#### Specialist Sales contact details:

**Gigi Sparling - Specialist Sales - European Financials**  
(44-20) 7134-0355  
ghislaine.sparling@jpmorgan.com

#### European Insurance most preferred stocks

Company	Rating	Target Price
Ageas	OW	€ 72.0
NN	OW	€ 75.0
Prudential	OW	1,325.0p
Beazley	OW	1,025.0p
Munich Re	OW	€ 650.0
Sampo	OW	€ 11.4

Source: J.P. Morgan. As of 03/12/2025

**See page 29 for analyst certification and important disclosures, including non-US analyst disclosures.**

J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

## Table Of Contents

---

<b>Love Actuary .....</b>	<b>1</b>
<b>Key Charts.....</b>	<b>6</b>
European Insurance Sector Valuations .....	7
<b>Catastrophe claims hitting \$100bn for the fifth year in a row but less damaging for the reinsurers .....</b>	<b>8</b>
Increase in retentions has shifted profitability to another level on top of price .....	9
<b>Key Sector Data .....</b>	<b>12</b>
IFRS17 valuation metrics .....	13
Price Performance .....	19
Consensus Estimates .....	21
Solvency II Ratio .....	22
Share buyback tracker.....	23
Macro Moves.....	25
<b>Our Latest Research.....</b>	<b>26</b>
<b>Previous Love Actuary Notes .....</b>	<b>27</b>
<b>Events Calendar.....</b>	<b>28</b>

Table 1: European Insurance: Key Valuation Metrics (Part 1)

Company	Analyst	Price	TP	JPM Rating	Upside	P/E (JPM adj.)			P/E (comprehensive)			Div yield			Total capital return yield			P/B (reported)			RoE			P/B (comprehensive)			RoE (comprehensive)			Adj. EPS CAGR	PEG (JPM adj.)
						25E	26E	27E	25E	26E	27E	25E	26E	27E	25E	26E	27E	25E	26E	27E	25E	26E	27E	25E	26E	27E	25E	26E	27E	24-27E	24-27E
Allianz	KH	371.6	360.0	N	-3%	13.2x	12.3x	11.5x	11.4x	10.3x	9.7x	4.6%	5.0%	5.4%	5.8%	6.2%	6.6%	2.3x	2.1x	2.0x	17.7%	17.8%	18.1%	1.8x	1.6x	1.5x	16.1%	16.5%	16.3%	8.3%	1.5x
AXA	FH	38.9	45.0	OW	16%	10.4x	9.8x	9.1x	10.4x	8.9x	8.3x	5.9%	6.3%	6.7%	11.4%	8.2%	8.2%	2.0x	1.9x	1.8x	18.8%	20.2%	20.4%	1.6x	1.5x	1.4x	15.5%	17.8%	18.0%	7.0%	1.4x
Generali	FH	34.2	40.0	OW	17%	12.2x	10.7x	10.0x	9.3x	8.7x	7.9x	4.6%	5.2%	5.7%	5.6%	6.1%	6.7%	1.6x	1.5x	1.5x	13.8%	14.7%	14.9%	1.3x	1.2x	1.1x	13.6%	13.4%	13.7%	11.8%	0.9x
Poste Italiane	FH	20.6	21.5	N	4%	11.8x	10.6x	10.5x	-	-	-	5.9%	6.0%	6.3%	5.9%	6.0%	6.3%	2.6x	2.3x	2.0x	18.3%	18.4%	17.4%	-	-	-	-	-	-	8.1%	1.3x
Zurich	KH	577.2	500.0	UW	-13%	16.1x	15.3x	14.4x	13.9x	15.3x	14.4x	4.2%	4.5%	4.7%	4.2%	4.5%	4.7%	3.7x	3.4x	3.2x	24.1%	23.3%	23.0%	3.1x	2.9x	2.7x	23.2%	19.5%	19.5%	7.6%	2.0x
<b>Composite Average</b>						<b>13.1x</b>	<b>12.1x</b>	<b>11.4x</b>	<b>11.5x</b>	<b>11.0x</b>	<b>10.3x</b>	<b>4.9%</b>	<b>5.2%</b>	<b>5.6%</b>	<b>6.6%</b>	<b>6.2%</b>	<b>6.5%</b>	<b>2.5x</b>	<b>2.3x</b>	<b>2.2x</b>	<b>18.9%</b>	<b>19.2%</b>	<b>19.2%</b>	<b>2.0x</b>	<b>1.9x</b>	<b>1.7x</b>	<b>17.4%</b>	<b>17.1%</b>	<b>17.1%</b>	<b>8.3%</b>	<b>1.5x</b>
Aegon	FH	7.0	8.5	OW	22%	6.4x	6.5x	5.5x	8.2x	6.8x	5.7x	5.8%	6.2%	6.6%	10.2%	16.5%	9.2%	1.3x	1.2x	1.0x	22.3%	19.5%	20.5%	0.8x	0.7x	0.6x	9.7%	10.8%	11.6%	34.5%	0.2x
Ageas	FH	58.9	72.0	OW	22%	8.8x	8.8x	7.0x	7.4x	7.4x	6.0x	6.4%	6.9%	7.5%	7.5%	6.9%	7.5%	1.2x	1.1x	1.1x	14.7%	13.3%	15.8%	0.8x	0.7x	0.7x	10.2%	10.3%	11.9%	10.1%	0.9x
ASR	FH	58.2	65.0	N	12%	10.2x	9.7x	9.3x	10.5x	10.1x	9.5x	5.8%	6.3%	6.8%	6.8%	7.7%	8.6%	1.3x	1.3x	1.2x	13.2%	13.2%	13.3%	0.9x	0.9x	0.9x	9.1%	9.1%	9.3%	7.4%	1.3x
NN Group	FH	62.5	75.0	OW	20%	8.2x	8.0x	7.6x	7.8x	7.4x	6.9x	5.9%	6.4%	6.8%	7.7%	8.4%	9.2%	0.8x	0.8x	0.7x	10.1%	9.9%	9.9%	0.7x	0.6x	0.6x	8.7%	8.9%	8.9%	6.7%	1.2x
<b>Benelux Average</b>						<b>8.4x</b>	<b>8.3x</b>	<b>7.4x</b>	<b>8.4x</b>	<b>7.9x</b>	<b>7.0x</b>	<b>6.0%</b>	<b>6.4%</b>	<b>6.9%</b>	<b>8.0%</b>	<b>9.7%</b>	<b>8.7%</b>	<b>1.1x</b>	<b>1.1x</b>	<b>1.0x</b>	<b>14.6%</b>	<b>13.6%</b>	<b>14.4%</b>	<b>0.8x</b>	<b>0.7x</b>	<b>0.7x</b>	<b>9.4%</b>	<b>9.7%</b>	<b>10.3%</b>	<b>13.8%</b>	<b>0.9x</b>
Sampo	NC	10.1	11.4	OW	12%	20.0x	17.6x	16.1x	20.0x	17.6x	16.1x	3.6%	3.9%	4.2%	4.9%	5.8%	6.4%	3.4x	3.4x	3.3x	18.3%	19.3%	20.8%	-	-	-	-	-	-	10.6%	1.7x
Storebrand	FH	157.4	135.0	UW	-14%	12.7x	12.1x	11.6x	11.8x	14.5x	13.4x	3.3%	3.6%	4.0%	5.5%	5.8%	6.2%	2.1x	1.9x	1.8x	16.9%	16.4%	15.9%	1.8x	1.7x	1.6x	15.9%	12.0%	12.2%	2.9%	-
Tryg	NC	159.5	165.0	N	3%	18.4x	18.8x	17.4x	18.4x	18.8x	17.4x	5.1%	5.4%	5.6%	6.7%	6.9%	6.7%	2.5x	2.6x	2.6x	13.6%	13.4%	15.0%	-	-	-	-	-	-	6.0%	3.1x
<b>Nordic Average</b>						<b>18.6x</b>	<b>17.3x</b>	<b>15.9x</b>	<b>18.4x</b>	<b>18.8x</b>	<b>17.4x</b>	<b>4.0%</b>	<b>4.3%</b>	<b>4.6%</b>	<b>5.5%</b>	<b>6.1%</b>	<b>6.5%</b>	<b>3.0x</b>	<b>3.0x</b>	<b>2.9x</b>	<b>16.8%</b>	<b>17.3%</b>	<b>18.5%</b>	<b>1.8x</b>	<b>1.7x</b>	<b>1.6x</b>	<b>15.9%</b>	<b>12.0%</b>	<b>12.2%</b>	<b>9.2%</b>	<b>1.9x</b>
Swiss Life	FH	880.8	715.0	UW	-19%	21.0x	18.9x	17.9x	20.1x	17.8x	16.7x	4.2%	4.5%	4.7%	6.2%	5.9%	5.3%	3.5x	3.6x	3.5x	16.4%	18.5%	19.3%	1.4x	1.4x	1.4x	7.2%	7.9%	8.3%	5.3%	3.6x
<b>Swiss Average</b>						<b>21.0x</b>	<b>18.9x</b>	<b>17.9x</b>	<b>20.1x</b>	<b>17.8x</b>	<b>16.7x</b>	<b>4.2%</b>	<b>4.5%</b>	<b>4.7%</b>	<b>6.2%</b>	<b>5.9%</b>	<b>5.3%</b>	<b>3.5x</b>	<b>3.6x</b>	<b>3.5x</b>	<b>16.4%</b>	<b>18.5%</b>	<b>19.3%</b>	<b>1.4x</b>	<b>1.4x</b>	<b>1.4x</b>	<b>7.2%</b>	<b>7.9%</b>	<b>8.3%</b>	<b>5.3%</b>	<b>3.6x</b>
Hannover Re	KH	258.6	320.0	OW	24%	12.0x	11.3x	10.9x	9.7x	9.3x	10.5x	4.6%	4.8%	5.0%	4.6%	4.8%	5.0%	2.5x	2.3x	2.1x	21.6%	21.1%	19.9%	1.6x	1.5x	1.4x	17.4%	16.7%	13.7%	7.2%	1.6x
Munich Re	KH	543.8	650.0	OW	20%	10.9x	10.6x	9.8x	10.9x	10.6x	9.8x	4.0%	4.4%	4.7%	7.6%	8.6%	9.6%	2.2x	2.0x	1.9x	20.0%	19.7%	19.5%	1.4x	1.3x	1.3x	13.1%	12.9%	12.9%	8.9%	1.2x
SCOR	KH	27.8	30.0	N	8%	6.1x	7.3x	7.1x	3.9x	9.5x	6.3x	6.8%	7.2%	7.6%	6.8%	7.2%	7.6%	1.2x	1.1x	1.0x	18.1%	15.2%	15.1%	0.6x	0.6x	0.6x	16.2%	6.4%	9.7%	516.2%	-
Swiss Re	KH	141.6	160.0	N	13%	10.3x	10.6x	10.1x	8.9x	9.9x	9.4x	4.4%	4.8%	5.1%	6.3%	6.7%	7.0%	2.1x	1.9x	1.8x	21.5%	18.6%	18.3%	1.4x	1.3x	1.2x	16.5%	13.6%	13.3%	16.5%	0.6x
<b>Reinsurance Average</b>						<b>10.8x</b>	<b>10.6x</b>	<b>10.0x</b>	<b>9.9x</b>	<b>10.1x</b>	<b>9.7x</b>	<b>4.4%</b>	<b>4.7%</b>	<b>5.0%</b>	<b>6.6%</b>	<b>7.2%</b>	<b>7.8%</b>	<b>2.2x</b>	<b>2.0x</b>	<b>1.9x</b>	<b>20.7%</b>	<b>19.5%</b>	<b>19.1%</b>	<b>1.4x</b>	<b>1.3x</b>	<b>1.3x</b>	<b>15.1%</b>	<b>13.7%</b>	<b>13.1%</b>	<b>27.4%</b>	<b>1.1x</b>
Aviva	FH	651.8	725.0	OW	11%	11.8x	10.7x	9.4x	11.7x	10.3x	9.0x	5.8%	6.3%	6.7%	5.8%	8.0%	8.5%	2.0x	1.9x	1.8x	17.9%	18.1%	19.7%	1.6x	1.6x	1.5x	13.8%	15.5%	16.9%	12.9%	0.8x
Legal and General	FH	246.9	275.0	N	11%	12.3x	10.9x	9.6x	11.7x	9.7x	8.4x	8.8%	9.0%	9.2%	12.4%	18.3%	10.7%	6.7x	6.6x	6.6x	47.4%	65.1%	73.9%	1.1x	1.0x	1.0x	10.0%	11.9%	13.0%	11.9%	0.9x
Phoenix	FH	696.0	605.0	UW	-13%	12.7x	10.4x	9.5x	8.4x	9.2x	8.5x	8.0%	8.2%	8.5%	8.0%	8.2%	8.5%	16.0x	30.0x	29.1x	67.1%	201.1%	313.4%	2.3x	2.4x	2.3x	25.6%	25.7%	27.9%	19.2%	0.5x
Prudential	FH	1,093.5	1,325.0	OW	21%	13.7x	11.2x	9.6x	8.4x	6.9x	5.9x	1.8%	2.0%	2.3%	5.1%	3.4%	4.0%	1.5x	1.3x	1.1x	15.3%	16.6%	17.2%	0.9x	0.8x	0.7x	11.5%	12.4%	12.9%	18.6%	0.6x
M&G	FH	272.4	315.0	OW	16%	11.1x	9.3x	8.6x	8.6x	7.6x	7.2x	7.5%	7.9%	8.3%	7.5%	7.9%	8.3%	2.0x	1.9x	1.7x	17.8%	20.5%	20.8%	1.0x	1.0x	0.9x	12.7%	13.4%	13.3%	12.1%	0.8x
<b>UK Life Average (ex-Pru)</b>						<b>12.0x</b>	<b>10.5x</b>	<b>9.4x</b>	<b>10.8x</b>	<b>9.6x</b>	<b>8.5x</b>	<b>7.3%</b>	<b>7.6%</b>	<b>7.9%</b>	<b>8.3%</b>	<b>11.1%</b>	<b>9.2%</b>	<b>5.4x</b>	<b>7.4x</b>	<b>7.2x</b>	<b>33.8%</b>	<b>59.3%</b>	<b>79.1%</b>	<b>1.5x</b>	<b>1.5x</b>	<b>1.4x</b>	<b>14.3%</b>	<b>15.7%</b>	<b>16.9%</b>	<b>13.4%</b>	<b>0.8x</b>
Admiral	KH	3,172.0	3,050.0	N	-4%	14.1x	13.9x	14.0x	14.1x	13.9x	14.0x	6.4%	6.5%	6.4%	6.4%	6.5%	6.4%	6.7x	6.4x	6.1x	49.2%	47.5%	44.9%	7.5x	5.7x	4.0x	63.7%	60.7%	56.7%	1.5%	9.1x
Beazley	KH	797.5	1,025.0	OW	29%	7.1x	7.7x	7.0x	7.1x	7.7x	7.0x	3.4%	3.8%	4.1%	10.5%	10.9%	11.3%	1.4x	1.3x	1.1x	20.6%	17.8%	17.7%	1.5x	1.3x	1.2x	21.5%	18.7%	18.4%	-4.2%	-
Hiscox	KH	1,340.0	1,500.0	OW	12%	11.2x	10.5x	9.5x	11.2x	10.5x	9.5x	2.8%	3.0%	3.1%	7.1%	7.3%	7.4%	1.5x	1.4x	1.2x	14.2%	13.8%	14.1%	1.6x	1.5x	1.3x	15.4%	15.1%	15.3%	1.5%	6.9x
Lancashire	KH	585.0	650.0	N	11%	5.7x	5.4x	5.3x	5.7x	5.4x	5.3x	13.9%	16.2%	16.8%	13.9%	16.2%	16.8%	1.3x	1.3x	1.2x	23.1%	24.3%	24.1%	1.3x	1.3x	1.3x	26.7%	28.0%	27.7%	4.1%	1.3x
<b>UK Non-Life Average</b>						<b>11.2x</b>	<b>11.1x</b>	<b>10.8x</b>	<b>11.2x</b>	<b>11.1x</b>	<b>10.8x</b>	<b>5.5%</b>	<b>5.8%</b>	<b>5.9%</b>	<b>8.1%</b>	<b>8.4%</b>	<b>8.5%</b>	<b>4.0x</b>	<b>3.8x</b>	<b>3.6x</b>	<b>33.6%</b>	<b>31.6%</b>	<b>30.4%</b>	<b>4.4x</b>	<b>3.5x</b>	<b>2.6x</b>	<b>40.7%</b>	<b>38.6%</b>	<b>36.7%</b>	<b>0.4%</b>	<b>5.9x</b>
<b>European Insurance</b>						<b>12.8x</b>	<b>11.9x</b>	<b>11.1x</b>	<b>11.2x</b>	<b>10.7x</b>	<b>10.0x</b>	<b>4.8%</b>	<b>5.2%</b>	<b>5.5%</b>	<b>6.7%</b>	<b>6.9%</b>	<b>7.0%</b>	<b>2.6x</b>	<b>2.6x</b>	<b>2.5x</b>	<b>20.1%</b>	<b>21.8%</b>	<b>23.2%</b>	<b>1.7x</b>	<b>1.6x</b>	<b>1.5x</b>	<b>15.9%</b>	<b>15.5%</b>	<b>15.5%</b>	<b>9.6%</b>	<b>1.5x</b>

Source: J.P. Morgan estimates. Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Table 2: European Insurance: Key Valuation Metrics (Part 2)

Company	Analyst	Price	TP	JPM Rating	Upside	P&C Combined ratio			P&C Re Combined ratio			Solvency II ratio			OCG yield			Hold Co. cash flow yield			New business CSM			CSM release ratio			CSM yoy growth rate		
						25E	26E	27E	25E	26E	27E	25E	26E	27E	25E	26E	27E	25E	26E	27E	25E	26E	27E	25E	26E	27E	25E	26E	27E
Allianz	KH	371.6	360.0	N	-3%	92.6%	92.7%	92.6%	-	-	-	212%	216%	219%	7.2%	7.5%	7.9%	-	-	-	4,951	5,138	5,293	7.3%	9.0%	9.0%	5.0%	6.2%	5.9%
AXA	FH	38.9	45.0	OW	16%	91.0%	91.0%	91.0%	-	-	-	219%	211%	231%	8.8%	8.6%	9.0%	7.3%	7.4%	7.8%	2,302	2,486	2,685	7.8%	7.8%	7.8%	0.0%	3.0%	3.3%
Generali	FH	34.2	40.0	OW	17%	92.5%	92.2%	91.9%	-	-	-	212%	209%	231%	9.2%	9.8%	10.5%	6.4%	6.7%	7.2%	2,935	3,339	3,758	9.0%	9.0%	9.0%	6.2%	4.9%	5.6%
Poste Italiane	FH	20.6	21.5	N	4%	-	-	-	-	-	-	315%	307%	299%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Zurich	KH	577.2	500.0	UW	-13%	92.9%	93.2%	92.8%	-	-	-	260%	262%	265%	5.5%	5.9%	6.2%	-	-	-	1,125	1,254	1,316	13.7%	12.6%	12.6%	10.3%	0.0%	0.0%
Aegon	FH	7.0	8.5	OW	22%	-	-	-	-	-	-	195%	186%	186%	8.1%	8.3%	9.4%	7.2%	7.4%	8.2%	647	622	645	10.8%	10.3%	10.2%	-10.7%	2.2%	2.4%
Ageas	FH	58.9	72.0	OW	22%	93.1%	92.6%	91.9%	-	-	-	200%	204%	209%	6.8%	6.5%	7.9%	6.4%	6.9%	7.5%	818	837	879	9.2%	9.2%	9.2%	-4.0%	3.6%	3.7%
ASR	FH	58.2	65.0	N	12%	94.0%	94.3%	94.2%	-	-	-	208%	219%	222%	11.3%	11.7%	12.2%	7.1%	7.8%	8.2%	-	-	-	6.9%	7.0%	7.1%	2.5%	3.3%	-0.7%
NN Group	FH	62.5	75.0	OW	20%	92.2%	92.0%	92.0%	-	-	-	207%	216%	226%	12.0%	12.4%	13.0%	9.6%	9.3%	9.6%	824	911	966	9.9%	10.1%	10.3%	1.8%	3.2%	3.4%
Sampo	NC	10.1	11.4	OW	12%	83.7%	83.2%	83.0%	-	-	-	176%	177%	181%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Storebrand	FH	157.4	135.0	UW	-14%	91.7%	90.9%	90.9%	-	-	-	197%	201%	204%	6.8%	7.1%	7.5%	6.1%	6.3%	6.4%	546	562	579	11.8%	11.8%	11.8%	3.9%	-8.0%	-7.6%
Tryg	NC	159.5	165.0	N	3%	80.4%	81.3%	81.1%	-	-	-	185%	176%	173%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Swiss Life	FH	880.8	715.0	UW	-19%	-	-	-	-	-	-	206%	204%	206%	4.8%	5.4%	5.6%	4.7%	5.1%	5.2%	625	643	663	7.1%	7.1%	7.1%	4.5%	0.7%	0.8%
Hannover Re	KH	258.6	320.0	OW	24%	-	-	-	87.8%	88.0%	88.0%	259%	259%	259%	-	-	-	-	-	-	457	380	380	12.8%	12.6%	12.5%	9.7%	8.8%	1.5%
Munich Re	KH	543.8	650.0	OW	20%	87.3%	89.9%	89.3%	74.8%	80.2%	81.4%	282%	274%	266%	-	-	-	-	-	-	2,143	1,190	1,207	7.3%	7.5%	7.5%	1.2%	-0.8%	-0.7%
SCOR	KH	27.8	30.0	N	8%	-	-	-	84.2%	86.5%	87.0%	215%	218%	221%	19.0%	12.8%	13.0%	-	-	-	392	410	400	7.0%	6.6%	6.6%	11.4%	-3.6%	2.2%
Swiss Re	KH	141.6	160.0	N	13%	89.3%	91.5%	92.0%	82.0%	84.3%	85.2%	263%	273%	275%	-	-	-	-	-	-	320	320	320	9.0%	8.1%	8.1%	4.9%	2.2%	2.1%
Aviva	FH	651.8	725.0	OW	11%	90.5%	89.6%	88.9%	-	-	-	177%	188%	192%	10.6%	8.0%	9.8%	10.6%	8.2%	9.6%	444	461	476	10.1%	10.1%	10.0%	1.8%	1.8%	1.9%
Legal and General	FH	246.9	275.0	N	11%	-	-	-	-	-	-	218%	215%	205%	4.8%	4.6%	5.0%	8.4%	8.6%	9.1%	616	694	743	7.8%	7.8%	7.8%	0.8%	1.7%	2.1%
Phoenix	FH	696.0	605.0	UW	-13%	-	-	-	-	-	-	176%	174%	180%	-	-	-	11.6%	14.3%	13.8%	124	215	217	7.6%	7.7%	7.7%	11.7%	3.2%	2.9%
Prudential	FH	1,093.5	1,325.0	OW	21%	-	-	-	-	-	-	220%	216%	216%	6.3%	8.3%	10.7%	3.0%	3.9%	5.1%	2,756	3,157	3,585	9.5%	9.5%	9.5%	14.9%	8.6%	9.6%
M&G	FH	272.4	315.0	OW	16%	-	-	-	-	-	-	242%	248%	256%	14.2%	12.3%	13.8%	8.6%	9.0%	9.8%	135	150	156	9.6%	10.5%	10.5%	11.0%	3.9%	3.4%
Admiral	KH	3,172.0	3,050.0	N	-4%	73.8%	74.4%	75.5%	-	-	-	211%	223%	230%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Beazley	KH	797.5	1,025.0	OW	29%	76.6%	78.4%	78.6%	-	-	-	240%	232%	210%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Hiscox	KH	1,340.0	1,500.0	OW	12%	85.0%	84.6%	84.3%	-	-	-	233%	232%	230%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Lancashire	KH	585.0	650.0	N	11%	78.9%	78.7%	79.2%	-	-	-	246%	251%	251%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Source: J.P. Morgan estimates. Bloomberg Finance L.P. Priced as of COB 03/12/2025.


Table 3: European Insurance: Key Valuation Metrics (Part 3)

Company	Analyst	Price	TP	JPM Rating	Upside	Reported SH equity (LC mn)				JPM adjusted profit (LC mn)				Tangible equity (LC mn)				Net CSM (LC mn)				Comprehensive equity (LC mn)				Comprehensive profit (LC mn)			
						24A	25E	26E	27E	24A	25E	26E	27E	24A	25E	26E	27E	24A	25E	26E	27E	24A	25E	26E	27E	24A	25E	26E	27E
Allianz	KH	371.6	360.0	N	-3%	59,717	62,494	65,385	68,495	9,938	10,827	11,401	12,106	40,873	44,110	47,001	50,111	34,544	36,263	38,511	40,773	75,417	80,373	85,512	90,884	11,762	12,546	13,648	14,368
AXA	FH	38.9	45.0	OW	16%	45,100	38,717	40,552	42,885	7,634	7,866	8,006	8,509	26,959	21,643	23,478	25,811	26,320	26,322	27,111	28,013	53,279	47,965	50,588	53,824	7,177	7,868	8,795	9,412
Generali	FH	34.2	40.0	OW	17%	30,389	31,999	33,811	35,743	3,802	4,302	4,851	5,173	18,528	20,148	21,960	23,892	21,484	22,817	23,926	25,255	40,012	42,965	45,886	49,147	3,237	5,635	5,960	6,502
Poste Italiane	FH	20.6	21.5	N	4%	11,583	13,213	14,134	15,040	2,013	2,271	2,518	2,545	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Zurich	KH	577.2	500.0	UW	-13%	25,472	28,196	30,311	32,526	5,806	6,455	6,813	7,235	20,667	22,678	24,793	27,007	10,100	11,141	11,141	11,141	30,767	33,819	35,934	38,148	6,206	7,496	6,813	7,235
Aegon	FH	7.0	8.5	OW	22%	7,215	7,914	7,716	8,540	855	1,689	1,527	1,668	6,640	7,339	7,141	7,965	6,975	6,227	6,362	6,515	13,615	13,565	13,504	14,481	462	1,324	1,457	1,617
Ageas	FH	58.9	72.0	OW	22%	7,752	9,294	9,824	10,636	1,158	1,251	1,273	1,612	7,226	7,493	8,023	8,835	7,200	6,909	7,156	7,422	14,426	14,402	15,180	16,257	1,478	1,477	1,521	1,877
ASR	FH	58.2	65.0	N	12%	8,779	9,118	9,396	9,620	1,069	1,182	1,224	1,269	8,187	8,521	8,799	9,023	4,211	4,317	4,460	4,427	12,398	12,837	13,259	13,450	925	1,150	1,185	1,237
NN Group	FH	62.5	75.0	OW	20%	19,831	20,102	20,737	21,332	1,844	2,015	2,024	2,089	18,602	18,891	19,526	20,121	5,458	5,555	5,734	5,932	24,060	24,446	25,260	26,053	2,441	2,112	2,203	2,286
Sampo	NC	10.1	11.4	OW	12%	7,059	7,833	7,813	7,725	1,193	1,359	1,511	1,614	-	-	-	-	-	-	-	-	7,059.0	7,833.3	7,813.3	7,725.0	1,193	1,359	1,511	1,614
Storebrand	FH	157.4	135.0	UW	-14%	31,358	33,378	35,172	37,026	5,508	5,477	5,608	5,748	24,637	27,185	29,391	31,595	10,941	11,365	10,453	9,658	35,578	38,551	39,844	41,254	7,700	5,902	4,696	4,953
Tryg	NC	159.5	165.0	N	3%	38,864	38,437	36,868	35,487	4,743	5,263	5,063	5,409	-	-	-	-	-	-	-	-	38,864	38,437	36,868	35,487	4,743	5,263	5,063	5,409
Swiss Life	FH	880.8	715.0	UW	-19%	7,271	6,935	6,808	6,903	1,211	1,162	1,269	1,326	5,540	5,203	5,076	5,171	11,327	11,834	11,915	12,007	16,867	17,037	16,991	17,178	1,368	1,214	1,350	1,418
Hannover Re	KH	258.6	320.0	OW	24%	11,795	12,390	13,704	15,064	2,329	2,609	2,749	2,867	11,715	12,312	13,626	14,985	6,122	6,716	7,308	7,417	17,837	19,027	20,934	22,402	2,677	3,202	3,342	2,976
Munich Re	KH	543.8	650.0	OW	20%	32,797	32,322	33,494	34,921	5,704	6,511	6,493	6,669	28,639	28,427	29,721	31,148	21,100	21,349	21,174	21,028	49,739	49,776	50,896	52,176	5,704	6,511	6,493	6,669
SCOR	KH	27.8	30.0	N	8%	4,524	4,522	4,470	4,812	3	820	684	700	3,640	3,640	3,588	3,930	4,091	4,558	4,395	4,490	7,731	8,198	7,983	8,420	-396	1,287	521	795
Swiss Re	KH	141.6	160.0	N	13%	21,892	25,163	26,703	28,296	3,241	5,048	4,833	5,019	17,842	21,125	22,665	24,258	15,453	16,215	16,576	16,922	33,295	37,340	39,240	41,180	1,344	5,810	5,194	5,365
Aviva	FH	651.8	725.0	OW	11%	7,609	10,092	10,251	10,677	1,288	1,584	1,841	2,063	5,025	6,270	6,429	6,855	5,858	5,963	6,068	6,186	10,883	12,232	12,497	13,041	1,530	1,598	1,920	2,159
Legal and General	FH	246.9	275.0	N	11%	3,053	2,103	1,952	1,925	1,151	1,223	1,320	1,432	3,023	2,073	1,922	1,895	10,257	10,341	10,522	10,742	13,280	12,414	12,444	12,637	1,339	1,286	1,479	1,631
Phoenix	FH	696.0	605.0	UW	-13%	1,213	438	233	240	437	554	675	742	1,075	298	93	100	2,443	2,728	2,816	2,898	3,518	3,026	2,908	2,998	740	839	762	824
Prudential	FH	1,093.5	1,325.0	OW	21%	17,492	18,604	20,629	22,960	2,452	2,753	3,254	3,738	16,644	17,715	19,740	22,071	20,145	23,150	25,139	27,546	36,789	40,865	44,879	49,617	4,176	4,468	5,301	6,073
M&G	FH	272.4	315.0	OW	16%	3,281	3,356	3,543	3,754	535	590	708	760	1,567	1,602	1,789	2,000	4,200	4,662	4,843	5,008	5,767	6,263	6,632	7,008	756	766	867	905
Admiral	KH	3,172.0	3,050.0	N	-4%	1,370	1,440	1,510	1,580	663	691	701	694	-	-	-	-	-	-	-	-	1,050	1,119	1,190	1,260	663	691	701	694
Beazley	KH	797.5	1,025.0	OW	29%	4,607	4,493	4,622	4,760	1,130	938	813	829	-	-	-	-	-	-	-	-	4,409	4,294	4,423	4,561	1,130	938	813	829
Hiscox	KH	1,340.0	1,500.0	OW	12%	3,689	3,932	4,062	4,221	627	539	553	583	-	-	-	-	-	-	-	-	3,380	3,603	3,733	3,892	627	539	553	583
Lancashire	KH	585.0	650.0	N	11%	1,493	1,448	1,494	1,534	321	340	357	364	-	-	-	-	-	-	-	-	1,296	1,251	1,297	1,337	321	340	357	364

Source: J.P. Morgan estimates. Bloomberg Finance L.P. Priced as of COB 03/12/2025.

## Key Charts

Figure 1: YTD price performance vs SXIP



Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Table 4: JPMe vs consensus estimates for key metrics

LCm (except for per share values), %


Company	Key Metric	JPM Estimate 2025	Consensus Estimate 2025	% difference	JPM Estimate 2026	Consensus Estimate 2026	% difference
Allianz	Op. Profit	16,827	17,207	-2%	17,420	17,851	-2%
AXA	Total underlying earnings	8,256	8,366	-1%	8,396	8,429	0%
Generali	Op. Profit before tax	7,987	7,895	1%	8,609	8,504	1%
Poste Italiane	Adjusted EBIT	3,242	3,201	1%	3,384	3,338	1%
Zurich	Business operating profit	8,681	8,714	0%	9,085	9,254	-2%
Aegon	Op. Profit before tax	1,695	1,680	1%	1,783	1,715	4%
Ageas	Net operating result	1,345	1,288	4%	1,367	1,419	-4%
ASR	Op. Profit before tax	1,580	1,587	0%	1,636	1,624	1%
NN Group	Op. Profit before tax	2,778	2,767	0%	2,791	2,730	2%
Sampo	Profit before tax	2,104	2,141	-2%	1,833	1,830	0%
Storebrand	Cash equivalent earnings before amortisation	5,554	5,508	1%	5,846	5,833	0%
Tryg	Profit before tax	7,088	7,047	1%	6,752	6,858	-2%
Swiss Life	Adj. profit from operations	1,821	1,870	-3%	1,875	1,943	-3%
Hannover Re	Net income	2,609	2,610	0%	2,749	2,752	0%
Munich Re	Net income	6,510	6,281	4%	6,493	6,410	1%
SCOR	Net income	818	803	2%	680	764	-11%
Swiss Re	Net income	5,048	4,766	6%	4,833	4,746	2%
Aviva	Op. Profit before tax	2,196	2,207	-1%	2,555	2,524	1%
Legal and General	Op. profit before tax	1,764	1,736	2%	1,825	1,822	0%
Phoenix	Adjusted op. profit	965	934	3%	1,105	1,096	1%
Prudential	Total segment profit	4,103	4,004	2%	4,643	4,356	7%
M&G	Op. Profit before tax	882	850	4%	1,040	937	11%
Admiral	Profit before tax	921	966	-5%	935	977	-4%
Beazley	Profit before tax	1,157	1,123	3%	1,029	1,001	3%
Hiscox	Profit before tax	644	663	-3%	651	664	-2%
Lancashire	Profit before tax	364	334	9%	380	339	12%

Source: J.P. Morgan estimates, Bloomberg Finance L.P. As of COB 03/12/2025.

## European Insurance Sector Valuations

**Figure 2: Insurance sector P/E relative to the market**


SXIP Index P/E relative to SXXP Index (Stoxx Europe 600), FY2 P/E



Source: Bloomberg Finance L.P., J.P. Morgan. Priced as of COB 03/12/2025.

**Figure 3: Insurance sector div yield relative to the market**

SXIP Index P/E relative to SXXP Index (Stoxx Europe 600), FY2 dividend yield




Source: Bloomberg Finance L.P., J.P. Morgan. Priced as of COB 03/12/2025.

## Catastrophe claims hitting \$100bn for the fifth year in a row but less damaging for the reinsurers

As we approach the end of 2025, it is clear that we will see another year in which global catastrophe claims have exceeded \$100bn. On an absolute basis, catastrophe claims have been increasing; a few years ago it was almost unthinkable that we would see the levels being seen now but \$100bn plus is now the new normal. Prior to 2021 there had only been 3 years which had exceeded \$100bn of insured losses and catastrophe years of this magnitude were expected to change the market, but this viewpoint has changed dramatically.

2025 will mark the fifth year in a row with catastrophe claims above \$100bn. Insured levels of catastrophe losses have been on an upward trend. Before 2021 there had only ever been 3 years in which global insured catastrophe losses had exceeded \$100bn based on data from Swiss Re. Since 2021 we have seen this level breached on an annual basis and this is likely to be the case again in 2025.


Figure 4: Global Nat cat insured losses



Source: Swiss Re data.



Figure 5: Nat Cat losses as percentage of GDP




Source: J.P. Morgan estimates.

### Catastrophe claims are in line with industry premium growth

We believe that the best way to think about catastrophe claims is relative to total insurance industry premiums and on this basis the impact is less noticeable.

Catastrophe claims between 1980-2025E have been equivalent to ~3% of non-life industry premiums and using the 2021-25E this ratio is 2.9%. On a rolling 10 year average, catastrophe claims relative to industry premiums have stayed relatively stable at ~3% of premiums. In fact, there has probably actually been a slight reduction in the level of catastrophe claims relative to the size of industry premiums.

Figure 6: Industry cat loss ratio has stayed relatively stable despite headline catastrophe losses increasing



Source: J.P. Morgan estimates using Swiss Re data.


### Increase in retentions has shifted profitability to another level on top of price

The narrative prior to 2023 was that catastrophe losses had increased and this had been a material headwind to the reinsurers who were responsible for taking on parts of catastrophe risk from the insurance markets. But looking at the evidence in the charts below, we can see that 2021-25E have been average years for catastrophe losses relative to the size of the industry using a 1980-2025E average.

What seems to have happened in our view is that there has been a shift in who has been responsible for paying claims. In the charts below, we can see that the reinsurers exceeded their catastrophe loss budgets in 2021 and 2022 but since 2023 have remained in line with or below budgets on average.


However if we look at 2023-2025 years at an industry level, they have not been material outliers in terms of being below average on claims. This suggests to us that the shift up that was seen in reinsurance retentions at the beginning of 2023 has made a meaningful difference to profitability for the industry.

Figure 7: 2021 Actual Nat Cat claims ratio vs. Budget




Source: Company reports.

Figure 8: 2022 Actual Nat Cat claims ratio vs. Budget




Source: Company reports.

Figure 9: 2023 Actual Nat Cat claims ratio vs. Budget




Source: Company reports.

Figure 10: 2024 Actual Nat Cat claims ratio vs. Budget



Source: Company reports.

Figure 11: 9M25 Actual Nat Cat claims ratio vs. Budget




Source: Company reports.

## Key Sector Data

## IFRS17 valuation metrics

Figure 12: Comprehensive P/BV vs. ROE


2026E Comprehensive ROE vs. 2025E Comprehensive P/BV



Source: J.P. Morgan estimates. Priced as of COB 03/12/2025.


Figure 13: Reported P/BV vs. ROE

2026E ROE vs. 2025E Reported P/BV




Source: J.P. Morgan estimates. Priced as of COB 03/12/2025.

Figure 14: Admiral 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 15: Aegon 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 16: Ageas 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 17: Allianz 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 18: ASR 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 19: Aviva 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 20: AXA 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 21: Beazley 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 22: Generali 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 23: Hannover Re 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 24: Hiscox 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 25: Legal & General 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 26: Lancashire 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 27: M&G 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 28: Munich Re 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 29: NN Group 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 30: Phoenix 2-yr forward P/E relative to SXIP



Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.


Figure 31: Poste Italiane 2-yr forward P/E relative to SXIP



Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.




Figure 32: Prudential 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 33: Sampo 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 34: SCOR 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 35: Storebrand 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 36: Swiss Life 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 37: Swiss Re 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 38: Tryg 2-yr forward P/E relative to SXIP



Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 39: Zurich Insurance 2-yr forward P/E relative to SXIP




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Price Performance

Figure 40: Insurance sector performance relative to the market


SXIP = European insurers, SXXP = European market (Stoxx indices)



Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 41: Insurance sector performance relative to the market


Based on SXIP Index price as a % of SXXP Index (Stoxx indices)



Source: Bloomberg Finance L.P., J.P. Morgan estimates. Priced as of COB 03/12/2025.

Figure 42: YTD performance of market sectors


% price change, based on Stoxx Europe 600 Index



Source: Bloomberg Finance L.P., J.P. Morgan. Priced as of COB 03/12/2025.

Figure 43: Sector price performance relative to European equity market

Based on Stoxx Europe 600 indices (SXIP vs SXXP)



Source: Bloomberg Finance L.P., J.P. Morgan. Priced as of COB 03/12/2025.

Table 5: Actual and relative price performance of our European Insurance coverage

%

Company	Price performance					Relative to SXXP					Relative to SXIP				
	YTD	3M	6M	1Y	2Y	YTD	3M	6M	1Y	2Y	YTD	3M	6M	1Y	2Y
Allianz	24%	4%	4%	23%	56%	10%	-2%	-1%	11%	32%	6%	2%	4%	6%	15%
AXA	11%	-3%	-10%	18%	32%	-2%	-8%	-14%	6%	9%	-7%	-5%	-10%	1%	-9%
Generali	24%	4%	6%	22%	79%	11%	-2%	2%	11%	55%	6%	2%	7%	5%	38%
Poste Italiane	49%	4%	8%	51%	105%	36%	-1%	3%	39%	81%	31%	3%	8%	34%	64%
Zurich	6%	0%	-2%	2%	30%	-8%	-5%	-7%	-10%	6%	-12%	-2%	-2%	-15%	-11%
<b>Average</b>	23%	2%	1%	23%	60%	9%	-4%	-3%	11%	37%	5%	0%	1%	6%	19%
Aegon	20%	5%	9%	13%	35%	6%	-1%	4%	1%	11%	1%	3%	9%	-4%	-6%
Ageas	20%	-4%	1%	18%	42%	7%	-9%	-4%	6%	19%	2%	-5%	1%	1%	1%
ASR	25%	-3%	2%	27%	36%	11%	-8%	-2%	15%	12%	7%	-4%	3%	10%	-5%
NN Group	47%	8%	10%	46%	78%	34%	3%	5%	34%	54%	29%	6%	10%	29%	37%
<b>Average</b>	28%	2%	5%	26%	48%	15%	-4%	1%	14%	24%	10%	0%	6%	9%	7%
Sampo	27%	4%	6%	21%	24%	13%	-1%	2%	9%	1%	9%	2%	7%	4%	-17%
Storebrand	28%	4%	15%	26%	64%	15%	-1%	11%	15%	40%	10%	3%	16%	9%	23%
Tryg	3%	-5%	-7%	-4%	6%	-10%	-11%	-12%	-16%	-18%	-15%	-7%	-7%	-21%	-35%
<b>Average</b>	19%	1%	5%	14%	31%	6%	-4%	0%	3%	8%	1%	-1%	5%	-3%	-10%
Swiss Life	24%	4%	6%	26%	53%	11%	-1%	1%	14%	30%	6%	2%	6%	9%	12%
<b>Average</b>	24%	4%	6%	26%	53%	11%	-1%	1%	14%	30%	6%	2%	6%	9%	12%
Hannover Re	5%	4%	-10%	0%	15%	-8%	-2%	-14%	-11%	-8%	-13%	2%	-9%	-17%	-25%
Munich Re	9%	1%	-7%	5%	36%	-4%	-5%	-12%	-6%	12%	-9%	-1%	-7%	-12%	-5%
SCOR	13%	-2%	-8%	17%	-8%	-1%	-7%	-13%	5%	-31%	-5%	-4%	-8%	0%	-48%
Swiss Re	5%	-2%	-4%	4%	40%	-8%	-7%	-9%	-8%	17%	-13%	-4%	-4%	-13%	-1%
<b>Average</b>	8%	0%	-7%	7%	21%	-5%	-5%	-12%	-5%	-3%	-10%	-2%	-7%	-10%	-20%
Aviva	36%	1%	5%	34%	52%	23%	-4%	0%	22%	28%	18%	0%	5%	17%	11%
Legal and General	9%	7%	-2%	12%	10%	-5%	1%	-6%	0%	-14%	-9%	5%	-2%	-5%	-31%
Phoenix	36%	6%	8%	34%	48%	22%	1%	3%	22%	24%	18%	4%	8%	17%	7%
Prudential	73%	13%	28%	71%	27%	59%	8%	24%	60%	3%	55%	11%	29%	54%	-14%
M&G	37%	6%	13%	35%	29%	24%	1%	9%	23%	5%	19%	5%	13%	18%	-12%
<b>Average</b>	38%	7%	10%	37%	33%	25%	1%	6%	25%	9%	20%	5%	11%	20%	-8%
Admiral	20%	-11%	-6%	19%	15%	7%	-17%	-11%	7%	-8%	2%	-13%	-6%	2%	-25%
Beazley	-6%	0%	-20%	-2%	42%	-19%	-6%	-24%	-14%	19%	-24%	-2%	-19%	-19%	1%
Hiscox	21%	3%	0%	22%	28%	7%	-3%	-5%	10%	4%	3%	1%	0%	5%	-13%
Lancashire	-2%	-3%	-4%	-14%	-9%	-16%	-9%	-9%	-26%	-32%	-20%	-5%	-4%	-31%	-50%
<b>Average</b>	8%	-3%	-8%	6%	19%	-5%	-8%	-12%	-6%	-4%	-10%	-5%	-7%	-11%	-22%
<b>European Insurance</b>	22%	2%	1%	21%	38%	9%	-4%	-3%	9%	14%	4%	0%	1%	4%	-3%

Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

## Consensus Estimates

Table 6: YTD % change in Bloomberg estimates


%

Company	YTD % change in EPS consensus estimates		YTD % change in DPS consensus estimates	
	2025	2026	2025	2026
Allianz	4.1%	4.4%	3.4%	3.1%
AXA	2.3%	1.3%	0.6%	0.0%
Generali	2.5%	5.2%	5.0%	7.2%
Poste Italiane	7.8%	9.1%	18.4%	18.8%
Zurich	4.5%	2.1%	12.2%	10.7%
<b>Average</b>	<b>4.2%</b>	<b>4.4%</b>	<b>7.9%</b>	<b>8.0%</b>
Aegon	0.3%	1.6%	-0.5%	1.4%
Ageas	-7.0%	-5.2%	1.2%	-0.4%
ASR	-3.7%	6.7%	0.0%	0.4%
NN Group	-17.1%	10.0%	0.4%	0.4%
<b>Average</b>	<b>-9.2%</b>	<b>3.8%</b>	<b>0.5%</b>	<b>0.1%</b>
Sampo	21.3%	7.0%	-4.7%	3.1%
Storebrand	5.9%	2.0%	-1.7%	-1.5%
Tryg	1.9%	-4.4%	-3.5%	-4.3%
<b>Average</b>	<b>9.7%</b>	<b>1.6%</b>	<b>-3.3%</b>	<b>-0.9%</b>
Swiss Life	2.2%	2.6%	-1.0%	-1.3%
<b>Average</b>	<b>2.2%</b>	<b>2.6%</b>	<b>-1.0%</b>	<b>-1.3%</b>
Hannover Re	5.5%	4.1%	25.6%	23.9%
Munich Re	4.0%	1.8%	25.7%	26.3%
SCOR	10.6%	-3.7%	1.3%	2.0%
Swiss Re	15.7%	3.4%	0.3%	1.8%
<b>Average</b>	<b>8.9%</b>	<b>1.4%</b>	<b>13.2%</b>	<b>13.5%</b>
Aviva	3.5%	5.3%	1.6%	1.7%
Legal and General	-13.2%	-7.4%	0.0%	0.0%
Phoenix	5.7%	31.1%	-0.4%	0.7%
Prudential	0.6%	-1.1%	10.0%	11.0%
M&G	4.9%	7.5%	-0.5%	-0.5%
<b>Average</b>	<b>0.3%</b>	<b>7.1%</b>	<b>2.2%</b>	<b>2.6%</b>
Admiral	24.5%	13.8%	21.2%	13.3%
Beazley	4.9%	-8.0%	74.5%	64.5%
Hiscox	-4.2%	-6.1%	19.7%	23.7%
Lancashire	-12.1%	-8.9%	9.4%	3.7%
<b>Average</b>	<b>3.3%</b>	<b>-2.3%</b>	<b>31.2%</b>	<b>26.3%</b>

Source: Bloomberg Finance L.P. estimates. As of COB 03/12/2025.


## Solvency II Ratio

Figure 44: 2025E Solvency II ratio



Source: J.P. Morgan estimates.

Figure 45: Gearing of IFRS NAV to BBB, lower-rated and unrated corporate credit at FY24



Source: J.P. Morgan estimates, Company data.

## Share buyback tracker


Table 7: European Insurance share buybacks

LCm, %

Bank	Buyback programme total size (lcy m)	% of current market cap	Amount completed (lcy m)	Amount completed (% based on lcy m)	Amount remaining (lcy m)	Amount remaining (%)	Estimated end date (# weeks)	Estimated end date	End date as per disclosures
<b>Ongoing</b>									
Generali	500	0.9%	471	94%	29	6%	1	08/12/2025	31/12/2025
Storebrand (2nd tranche)	750	1.1%	669	89%	81	11%	2	18/12/2025	19/12/2025
Aegon	400	3.5%	352	88%	48	12%	3	21/12/2025	15/12/2025
NN	300	1.8%	262	87%	38	13%	5	08/01/2026	31/12/2025
Prudential (3rd tranche)	500	1.3%	435	87%	65	13%	3	24/12/2025	24/12/2025
AXA	3,800	4.6%	3,100	82%	700	18%	5	04/01/2026	26/02/2026
Munich Re (2025-26)	2,000	2.8%	1,432	72%	568	28%	1	11/12/2025	29/04/2026
Hiscox (2nd Tranche) (USD)	138	2.4%	98	71%	40	29%	3	26/12/2025	31/03/2026
Swiss Life	750	3.0%	498	66%	252	34%	22	08/05/2026	31/05/2026
Sampo	150	0.6%	43	29%	107	71%	9	02/02/2026	30/01/2026
Prudential (2026)	500	1.8%	Not started	Not started	Not started	Not started	Not started		
Prudential (2027)	600	2.1%	Not started	Not started	Not started	Not started	Not started		
<b>Recently completed</b>									
Storebrand (2025)	750	1.2%	750	100.0%				Completed as of 25 Jun 2025	
Prudential (US\$) (2nd tr: 2025)	800	3.4%	800	100.0%				Completed on 27 Jun 2025	
Aegon (2025)	150	1.5%	150	100.0%				Completed on 30 Jun 2025	
Ageas	200	1.7%	200	100.0%				Completed on 31 July 2025	
Legal & General	500	3.7%	500	100.0%				Completed on 03 Sep 2025	
Allianz	2,000	1.5%	2,000	100.0%				Completed on 17 Sep 2025	
Hiscox (1st Tranche) (USD)	138	2.2%	138	100.0%				Completed on 03 Oct 2025	
Beazley	500	6.9%	500	100.0%				Completed on 20 Oct 2025	
Sampo	200	0.8%	200	100.0%				Completed on 31 Oct 2025	


Source: Company reports, Bloomberg Finance L.P. and J.P. Morgan estimates. Data as of 02/12/2025.

Figure 46: Ongoing share buyback programmes, as % of market cap



Source: Company reports and J.P. Morgan estimates. All on total announced SBB basis. Data as of 02/12/2025.

Figure 47: Ongoing share buyback progress - % of progress remaining



Source: Company reports and J.P. Morgan estimates. Prudential announced a \$500m share buyback for 2026 and a \$600m share buyback for 2027 on 26 Aug 2025. Hiscox completed the initial tranche of \$137.5 m on 3 October 2025 and commenced the second tranche of a maximum \$137.5m on 6th October 2025. Beazley completed its share repurchase programme of amount of \$500 m. Sampo plc has completed its EUR 200 million share buyback programme on 31<sup>st</sup> October 2025. Sampo plc started its share buyback programme of EUR 150 million on 6<sup>th</sup> November 2025. Data as of 02/12/2025.




Macro Moves

Figure 48: YTD change in sovereign yields




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 49: YTD equity market movements




Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

Figure 50: YTD change in Corporate Credit Spread for Euro and US bonds



Source: J.P. Morgan. Priced as of COB 03/12/2025.

Figure 51: YTD change in Euro and GBP 10-yr swap rates



Source: Bloomberg Finance L.P. Priced as of COB 03/12/2025.

## Our Latest Research

European Financials: Key takeaways from our 2nd European Financials Conference	<a href="#">link</a>
UK Life Insurance: UK life stress tests show individual company resilience - but read with a pinch of salt	<a href="#">link</a>
European Flow Tracker: Resilient active net flows in Europe in October	<a href="#">link</a>
European Financials: Mapping the agenda: Key Topics and Questions for European Financials heading into our Conference	<a href="#">link</a>
Sampo: A safe haven in a weakening P&C pricing cycle with upside to capital returns	<a href="#">link</a>
European Flow Tracker: Stronger net flows in Q3, with an improvement seen across our coverage	<a href="#">link</a>
From Chips to Cars: Deep Dive into ADAS and Robotaxis: A Cross-Sector Deep Dive into Autonomous Mobility and Robotaxis	<a href="#">link</a>
Sampo: Reasons to remain positive - increasing PT to €11.4 and updating estimates ahead of 3Q25 results	<a href="#">link</a>
European Reinsurance: Reinsurance Renaissance #9 - Lessons from the last soft market: OW Hannover Re and Munich Re; d/g Swiss Re to Neutral	<a href="#">link</a>
Aegon: A decision to re-domicile to the US highlights substantial SOTP upside - raising PT to €8.50	<a href="#">link</a>
European Flow Tracker: Strong August flows in Europe, flat M/M in the US	<a href="#">link</a>
EU Spotlight: Ain't no mountain high enough? Assessing earnings expectations into H2'25 reporting	<a href="#">link</a>
Italian Financials: Milan tour - constructive feedback	<a href="#">link</a>
Prudential Plc: Not just a growth story - we expect ~10% FCF yield by 2028E	<a href="#">link</a>
European Flow Tracker: July outflows in European passive equity funds	<a href="#">link</a>
Legal and General Group PLC: Downgrading to Neutral on valuation, earnings outlook and competition risks	<a href="#">link</a>
Storebrand: Raising estimates for better Insurance margin outlook; but stock continues to look expensive - reiterating UW	<a href="#">link</a>
UK Motor Insurance : No price caps on premium finance but other concerns to be examined	<a href="#">link</a>
European Flow Tracker: Q2 25 flows point to preference for European over US funds	<a href="#">link</a>
Italian Insurance: Upgrade Generali to OW, downgrade Poste Italiane to N	<a href="#">link</a>
Munich Re: ROE improvement likely to drive the next leg - upgrading to OW	<a href="#">link</a>
Legal and General Group PLC: Reducing our estimates for Asset Management division post Deep Dive	<a href="#">link</a>
Prudential Plc: Placing on Positive Catalyst Watch into 1H25 due to earnings, capital management and Indian divestment	<a href="#">link</a>
European Flow Tracker: May net flow recovery, with better momentum in Europe	<a href="#">link</a>
Sampo: Recalibrating capital return assumptions & addressing the key debates	<a href="#">link</a>
Dutch Insurance: Upgrading NN to Overweight following CMD; downgrading ASR to Neutral	<a href="#">link</a>
Legal and General Group plc: Model update for Meiji Yasuda and FY24 results; possible Asset Management target upgrade	<a href="#">link</a>
M&G plc: Dai-ichi Life partnership with M&G: Positive for the shares	<a href="#">link</a>
European Flow Tracker: Fixed income plunge in April	<a href="#">link</a>
Nordics Insurance: Stepping out of the shadows amidst wider P&C slowdown - U/G Sampo to OW & initiate on Tryg at N	<a href="#">link</a>
Prudential plc: The path to cash - reiterating OW	<a href="#">link</a>
European Flow Tracker: March flows slow down, but Europe more resilient than the US	<a href="#">link</a>
European Reinsurance: Reinsurance Renaissance #8: Euro reinsurers more resilient to falling prices than previous cycles	<a href="#">link</a>
Ageas: Esure deal is slightly accretive to earnings, highly accretive to cash flow, and good deal in our view	<a href="#">link</a>
European Insurance: Here are the sensitivities - why we're not panicking (yet)	<a href="#">link</a>
Allianz: Strong fundamental story but stock more than up with events - resuming at N	<a href="#">link</a>
Lloyd's and London market insurers: Feedback from walking tour	<a href="#">link</a>
European Flow Tracker: Improving active flows in February, with Schroders standing out	<a href="#">link</a>
Poste Italiane SPA: Cash machine - upgrading Poste Italiane to Overweight	<a href="#">link</a>
Storebrand: As tailwinds decline, we recommend going Dutch - reinstating coverage with UW	<a href="#">link</a>
European Flow Tracker: A slow start to 2025, with January flows lower M/M	<a href="#">link</a>
Prudential plc: Partial divestment of ICICI Prudential Asset Management could be positive	<a href="#">link</a>
Legal and General Group plc: Sale of US business: additional buyback, strategic stake and private markets opportunity	<a href="#">link</a>
Generali: A solid strategic plan, but immaterial forecast change and valuation risks skewed to downside; for now we remain Neutral	<a href="#">link</a>
Aviva plc: Assessing the Direct Line opportunity - upgrade to OW on mix, execution and revenue synergy potential	<a href="#">link</a>
European Flow Tracker: Strong Q4 net flows driven by notable increase in passive equities	<a href="#">link</a>
Aegon: Thought experiments: value creation beyond our base case	<a href="#">link</a>

## Previous Love Actuary Notes

Love Actuary: #170 - Are earnings upgrades for the insurance sector starting to tail off?	<a href="#">link</a>
Love Actuary: #169 - UK Motor pricing continues to soften in 2025	<a href="#">link</a>
Love Actuary: #168 - Managing earnings a key part of the reinsurance story	<a href="#">link</a>
Love Actuary: #167 - Private credit and illiquid asset exposure of European insurers	<a href="#">link</a>
Love Actuary: #166 - Insights from 2Q25 Hong Kong life insurance market data	<a href="#">link</a>
Love Actuary: #165 - Reinsurance balance sheets offer support for capital returns	<a href="#">link</a>
Love Actuary: #164 - Results were stronger than expected in the last soft market	<a href="#">link</a>
Love Actuary: #163 - Investor feedback on European insurers in recent months	<a href="#">link</a>
Love Actuary: #162 - Q3 25 likely to be positive due to light nat cats but storms could still hit in October	<a href="#">link</a>
Love Actuary: #161 - Regulatory change in UK workplace pensions driving consolidation: positive for UK life insurers	<a href="#">link</a>
Love Actuary: #160 - Insurers continue to offer strong earnings momentum	<a href="#">link</a>
Love Actuary: #159 - Considering the implications of a quiet hurricane season so far	<a href="#">link</a>
Love Actuary: #158 - Taking the temperature of the reinsurance market ahead of Monte Carlo	<a href="#">link</a>
Love Actuary: #157 - Minimal French sovereign risk in European Insurance	<a href="#">link</a>
Love Actuary: #156 - A framework for analysing profitability and margins under IFRS17	<a href="#">link</a>
Love Actuary: #155 - Cat Bond issuance has reached record levels in 2025	<a href="#">link</a>
Love Actuary: #154 - Insights from 1Q25 Hong Kong life insurance market data	<a href="#">link</a>
Love Actuary: #153 - Unconvincing evidence that UK motor consolidation will improve the market	<a href="#">link</a>
Love Actuary: #152 - UK motor insurance prices stabilising but margins still likely to be hit	<a href="#">link</a>
Love Actuary: #151 - CSM revisited	<a href="#">link</a>
Love Actuary: #150 - Reasons to remain (selectively) invested in European insurers	<a href="#">link</a>
Love Actuary: #149 - 2Q 25 a benign quarter for catastrophes	<a href="#">link</a>
Love Actuary: #148 - Share buybacks to continue to support attractive sector capital returns	<a href="#">link</a>
Love Actuary: #147 - UK Life Insurance Stress Test 2025 - not a cause for concern, in our view	<a href="#">link</a>
Love Actuary: #146 - Low interest rates in China not a concern for Ageas or Prudential	<a href="#">link</a>
Love Actuary: #145 - Is hurricane season weakness still justified?	<a href="#">link</a>
Love Actuary: #144 - Mid-year Renewals likely to show softening trend continuing	<a href="#">link</a>
Love Actuary: #143 - What are UK life insurers doing in the gilts market?	<a href="#">link</a>
Love Actuary: #142 - Insights from 4Q24 Hong Kong life insurance market data	<a href="#">link</a>
Love Actuary: #141 - Is the insurance sector priced for perfection?	<a href="#">link</a>
Love Actuary: #140 - Pricing tailwind of the past eight years shifting to a headwind	<a href="#">link</a>
Love Actuary: #139 - Post-tariffs: insurers have been resilient, and we would remain constructive	<a href="#">link</a>
Love Actuary: #138 - 1Q25 Nat Cat the highest since 2011 - less risk to earnings at Lloyd's insurers than Euro reinsurers	<a href="#">link</a>
Love Actuary: #137 - US tariffs and European insurers	<a href="#">link</a>
Love Actuary: #136 - Strong sector performance relative to earnings leaves sector valuation looking more balanced	<a href="#">link</a>
Love Actuary: #135 - European macro and how this affects insurers	<a href="#">link</a>
Love Actuary: #134 - Hot Topics - Spring edition	<a href="#">link</a>
Love Actuary: #133 - Reinsurers face uncertain earnings horizon for 2025	<a href="#">link</a>
Love Actuary: #132 - An updated analysis of CSM and its key ratios	<a href="#">link</a>
Love Actuary: #131 - An update on the UK retail annuity market - set to grow at double-digit rates	<a href="#">link</a>
Love Actuary: #130 - Break in case of emergency - launching our natural catastrophe impact database	<a href="#">link</a>
Love Actuary: #129 - Commercial pricing slowing down	<a href="#">link</a>
Love Actuary: #128 - Insights from Hong Kong life insurance market data, 3Q24	<a href="#">link</a>
Love Actuary: #127 - The impact of higher yields on UK life stocks	<a href="#">link</a>
Love Actuary: #126 - 4Q24 Nat Cat unlikely to be too severe	<a href="#">link</a>
Love Actuary: #125 - Reinsurance prices down but still at good levels	<a href="#">link</a>
Love Actuary: #124 - 'Tis the season for reinsurance	<a href="#">link</a>

Events Calendar

October 2025				
M	T	W	T	F
		1	2	3
6	7	8	9	10
13	14	15	16	17
20	21	22	23	24
27	28	29	30	31

November 2025				
M	T	W	T	F
3	4	5	6	7
10	11	12	13	14
17	18	19	20	21
24	25	26	27	28

December 2025				
M	T	W	T	F
1	2	3	4	5
8	9	10	11	12
15	16	17	18	19
22	23	24	25	26

Investor Days	
AXA Roundtable event	15-Sep-25
Generali Deep Dive on Distribution & Customers	02-Oct-25
Hannover Re Investors' Day	09-Oct-25
Legal & General Retail Investor Deep Dive	23-Oct-25
Aviva In focus event	13-Nov-25
Zurich Investor Update	18-Nov-25
Admiral UK Household Deep Dive	26-Nov-25
Inside Allianz series	28-Nov-25
Lancashire Investor Event	02-Dec-25
Swiss Re Management Dialogues	05-Dec-25
Aegon Capital Markets Day	10-Dec-25
Storebrand Capital Markets Day	10-Dec-25
Munich Re investor day	11-Dec-25
Beazley Capital Markets Session	25-Nov-25

October 2025		
10	Tryg	3Q25 results
22	Storebrand	3Q25 results
29	Prudential Plc	3Q25 results
30	AXA	3Q25 results
31	SCOR	3Q25 results

November 2025		
5	Lancashire	3Q25 results
5	M&G	3Q25 results
5	Sampo	3Q25 results
6	Hiscox	3Q25 results
6	Zurich	3Q25 results
10	Hannover Re	3Q25 results
11	Munich Re	3Q25 results
12	Swiss Life	3Q25 results
13	Aegon	3Q25 results
13	Aviva	3Q25 results
13	Generali	3Q25 results
13	Poste Italiane	3Q25 results
14	Allianz	3Q25 results
14	Swiss Re	3Q25 results
25	Beazley	3Q25 results

**Analyst Certification:** The Research Analyst(s) denoted by an “AC” on the cover of this report certifies (or, where multiple Research Analysts are primarily responsible for this report, the Research Analyst denoted by an “AC” on the cover or within the document individually certifies, with respect to each security or issuer that the Research Analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect the Research Analyst’s personal views about any and all of the subject securities or issuers; and (2) no part of any of the Research Analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the Research Analyst(s) in this report. For all Korea-based Research Analysts listed on the front cover, if applicable, they also certify, as per KOFIA requirements, that the Research Analyst’s analysis was made in good faith and that the views reflect the Research Analyst’s own opinion, without undue influence or intervention.

All authors named within this report are Research Analysts who produce independent research unless otherwise specified. In Europe, Sector Specialists (Sales and Trading) may be shown on this report as contacts but are not authors of the report or part of the Research Department.

## Important Disclosures

**Company-Specific Disclosures:** Important disclosures, including price charts and credit opinion history tables (if applicable), are available for compendium reports and all J.P. Morgan–covered companies, and certain non-covered companies, by visiting <https://www.jpmm.com/research/disclosures>, calling 1-800-477-0406, or e-mailing [research.disclosure.inquiries@jpmorgan.com](mailto:research.disclosure.inquiries@jpmorgan.com) with your request.

### Explanation of Equity Research Ratings, Designations and Analyst(s) Coverage Universe:

J.P. Morgan uses the following rating system: Overweight (over the duration of the price target indicated in this report, we expect this stock will outperform the average total return of the stocks in the Research Analyst’s, or the Research Analyst’s team’s, coverage universe); Neutral (over the duration of the price target indicated in this report, we expect this stock will perform in line with the average total return of the stocks in the Research Analyst’s, or the Research Analyst’s team’s, coverage universe); and Underweight (over the duration of the price target indicated in this report, we expect this stock will underperform the average total return of the stocks in the Research Analyst’s, or the Research Analyst’s team’s, coverage universe. NR is Not Rated. In this case, J.P. Morgan has removed the rating and, if applicable, the price target, for this stock because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating and, if applicable, the price target, no longer should be relied upon. An NR designation is not a recommendation or a rating. Some stocks under coverage have a rating but no price target; in these cases, we expect the stock will outperform/perform in line/underperform the average total return of the stocks in the Research Analyst’s, or the Research Analyst’s team’s, coverage universe of the relevant duration of the region. In our Asia (ex-Australia and ex-India) and U.K. small- and mid-cap Equity Research, each stock’s expected total return is compared to the expected total return of a benchmark country market index, not to those Research Analysts’ coverage universe. If it does not appear in the Important Disclosures section of this report, the certifying Research Analyst’s coverage universe can be found on J.P. Morgan’s Research website, <https://www.jpmorganmarkets.com>.

**Coverage Universe: Hossain, Kamran M:** Admiral Group Plc (ADML.L), Allianz (ALVG.DE), Beazley (BEZG.L), Hannover Re (HNRGn.DE), Hiscox (HSX.L), Lancashire (LRE.L), Munich Re (MUVGn.DE), SCOR (SCOR.PA), Swiss Re (SRENH.S), Zurich Insurance Group AG (ZURN.S)

### J.P. Morgan Equity Research Ratings Distribution, as of October 04, 2025

	Overweight (buy)	Neutral (hold)	Underweight (sell)
J.P. Morgan Global Equity Research Coverage*	50%	38%	12%
IB clients**	50%	48%	35%
JPMS Equity Research Coverage*	48%	40%	12%
IB clients**	73%	69%	52%

\*Please note that the percentages may not add to 100% because of rounding.

\*\*Percentage of subject companies within each of the "buy," "hold" and "sell" categories for which J.P. Morgan has provided investment banking services within the previous 12 months.

For purposes of FINRA ratings distribution rules only, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. Please note that stocks with an NR designation are not included in the table above. This information is current as of the end of the most recent calendar quarter.

**Equity Valuation and Risks:** For valuation methodology and risks associated with covered companies or price targets for covered companies, please see the most recent company-specific research report at <http://www.jpmorganmarkets.com>, contact the primary analyst or your J.P. Morgan representative, or email [research.disclosure.inquiries@jpmorgan.com](mailto:research.disclosure.inquiries@jpmorgan.com). For material information about the proprietary models used, please see the Summary of Financials in company-specific research reports and the Company Tearsheets, which are available to download on the company pages of our client website, <http://www.jpmorganmarkets.com>. This report also sets out within it the material underlying assumptions used.

### History of Investment Recommendations:

A history of J.P. Morgan investment recommendations disseminated during the preceding 12 months can be accessed on the Research &

Commentary page of <http://www.jpmorganmarkets.com> where you can also search by analyst name, sector or financial instrument.

**Analysts' Compensation:** The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

**Registration of non-US Analysts:** Unless otherwise noted, the non-US analysts listed on the front of this report are employees of non-US affiliates of J.P. Morgan Securities LLC, may not be registered as research analysts under FINRA rules, may not be associated persons of J.P. Morgan Securities LLC, and may not be subject to FINRA Rule 2241 or 2242 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

## Other Disclosures

---

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide.

**UK MIFID FICC research unbundling exemption:** UK clients should refer to [UK MIFID Research Unbundling exemption](#) for details of J.P. Morgan's implementation of the FICC research exemption and guidance on relevant FICC research categorisation.

All research material made available to clients are simultaneously available on our client website, J.P. Morgan Markets, unless specifically permitted by relevant laws. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research material available on a particular stock, please contact your sales representative.

Any long form nomenclature for references to China; Hong Kong; Taiwan; and Macau within this research material are Mainland China; Hong Kong SAR (China); Taiwan (China); and Macau SAR (China).

J.P. Morgan Research may, from time to time, write on issuers or securities targeted by economic or financial sanctions imposed or administered by the governmental authorities of the U.S., EU, UK or other relevant jurisdictions (Sanctioned Securities). Nothing in this report is intended to be read or construed as encouraging, facilitating, promoting or otherwise approving investment or dealing in such Sanctioned Securities. Clients should be aware of their own legal and compliance obligations when making investment decisions.

Any digital or crypto assets discussed in this research report are subject to a rapidly changing regulatory landscape. For relevant regulatory advisories on crypto assets, including bitcoin and ether, please see <https://www.jpmorgan.com/disclosures/cryptoasset-disclosure>.

The author(s) of this research report may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so.

**Exchange-Traded Funds (ETFs):** J.P. Morgan Securities LLC ("JPMS") acts as authorized participant for substantially all U.S.-listed ETFs. To the extent that any ETFs are mentioned in this report, JPMS may earn commissions and transaction-based compensation in connection with the distribution of those ETF shares and may earn fees for performing other trade-related services, such as securities lending to short sellers of the ETF shares. JPMS may also perform services for the ETFs themselves, including acting as a broker or dealer to the ETFs. In addition, affiliates of JPMS may perform services for the ETFs, including trust, custodial, administration, lending, index calculation and/or maintenance and other services.

**Options and Futures related research:** If the information contained herein regards options- or futures-related research, such information is available only to persons who have received the proper options or futures risk disclosure documents. Please contact your J.P. Morgan Representative or visit <https://www.theocc.com/components/docs/riskstoc.pdf> for a copy of the Option Clearing Corporation's Characteristics and Risks of Standardized Options or [https://www.finra.org/sites/default/files/2020-08/Security\\_Futures\\_Risk\\_Disclosure\\_Statement\\_2020.pdf](https://www.finra.org/sites/default/files/2020-08/Security_Futures_Risk_Disclosure_Statement_2020.pdf) for a copy of the Security Futures Risk Disclosure Statement.

**Changes to Interbank Offered Rates (IBORs) and other benchmark rates:** Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: [https://www.jpmorgan.com/global/disclosures/interbank\\_offered\\_rates](https://www.jpmorgan.com/global/disclosures/interbank_offered_rates)

**Private Bank Clients:** Where you are receiving research as a client of the private banking businesses offered by JPMorgan Chase & Co. and its subsidiaries ("J.P. Morgan Private Bank"), research is provided to you by J.P. Morgan Private Bank and not by any other division of J.P. Morgan, including, but not limited to, the J.P. Morgan Corporate and Investment Bank and its Global Research division.

**Legal entity responsible for the production and distribution of research:** The legal entity identified below the name of the Reg AC Research Analyst who authored this material is the legal entity responsible for the production of this research. Where multiple Reg AC Research Analysts authored this material with different legal entities identified below their names, these legal entities are jointly responsible for the production of this research. Where more than one legal entity is listed under an analyst's name, the first legal entity is responsible for the production unless stated otherwise. Research Analysts from various J.P. Morgan affiliates may have contributed to the production of this material but may not be licensed to carry out regulated activities in your jurisdiction (and do not hold themselves out as being able to do so). Unless otherwise stated below in the legal entity disclosures, this material has been distributed by the legal entity responsible for production, or where more than one legal entity is listed under the analyst's name, the first legal entity will be responsible for distribution. If you have any queries, please contact the relevant Research Analyst in your jurisdiction or the entity in your jurisdiction that has distributed this research material.



#### Legal Entities Disclosures and Country-/Region-Specific Disclosures:

**Argentina:** JPMorgan Chase Bank N.A Sucursal Buenos Aires is regulated by Banco Central de la República Argentina (“BCRA”- Central Bank of Argentina) and Comisión Nacional de Valores (“CNV”- Argentinian Securities Commission - ALYC y AN Integral N°51).

**Australia:** J.P. Morgan Securities Australia Limited (“JPMSAL”) (ABN 61 003 245 234/AFS Licence No: 238066) is regulated by the Australian Securities and Investments Commission and is a Market Participant of ASX Limited, a Clearing and Settlement Participant of ASX Clear Pty Limited and a Clearing Participant of ASX Clear (Futures) Pty Limited. This material is issued and distributed in Australia by or on behalf of JPMSAL only to “wholesale clients” (as defined in section 761G of the Corporations Act 2001). A list of all financial products covered can be found by visiting <https://www.jpmm.com/research/disclosures>. J.P. Morgan seeks to cover companies of relevance to the domestic and international investor base across all Global Industry Classification Standard (GICS) sectors, as well as across a range of market capitalisation sizes. If applicable, in the course of conducting public side due diligence on the subject company(ies), the Research Analyst team may at times perform such diligence through corporate engagements such as site visits, discussions with company representatives, management presentations, etc. Research issued by JPMSAL has been prepared in accordance with J.P. Morgan Australia’s Research Independence Policy which can be found at the following link: [J.P. Morgan Australia - Research Independence Policy](#).

**Brazil:** Banco J.P. Morgan S.A. is regulated by the Comissao de Valores Mobiliarios (CVM) and by the Central Bank of Brazil. Ombudsman J.P. Morgan: 0800-7700847 / 0800-7700810 (For Hearing Impaired) / [ouvidoria.jp.morgan@jpmchase.com](mailto:ouvidoria.jp.morgan@jpmchase.com).

**Canada:** J.P. Morgan Securities Canada Inc. is a registered investment dealer, regulated by the Canadian Investment Regulatory Organization and the Ontario Securities Commission and is the participating member on Canadian exchanges. This material is distributed in Canada by or on behalf of J.P.Morgan Securities Canada Inc.

**Chile:** Inversiones J.P. Morgan Limitada is an unregulated entity incorporated in Chile.

**China:** J.P. Morgan Securities (China) Company Limited has been approved by CSRC to conduct the securities investment consultancy business.

**Colombia:** Banco J.P. Morgan Colombia S.A. is supervised by the Superintendencia Financiera de Colombia (SFC).

**Dubai International Financial Centre (DIFC):** JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered address is Dubai International Financial Centre - The Gate, West Wing, Level 3 and 9 PO Box 506551, Dubai, UAE. This material has been distributed by JP Morgan Chase Bank, N.A., Dubai Branch to persons regarded as professional clients or market counterparties as defined under the DFSA rules.

**European Economic Area (EEA):** Unless specified to the contrary, research is distributed in the EEA by J.P. Morgan SE (“JPM SE”), which is authorised as a credit institution by the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB). JPM SE is a company headquartered in Frankfurt with registered address at TaunusTurm, Taunustor 1, Frankfurt am Main, 60310, Germany. The material has been distributed in the EEA to persons regarded as professional investors (or equivalent) pursuant to Art. 4 para. 1 no. 10 and Annex II of MiFID II and its respective implementation in their home jurisdictions (“EEA professional investors”). This material must not be acted on or relied on by persons who are not EEA professional investors. Any investment or investment activity to which this material relates is only available to EEA relevant persons and will be engaged in only with EEA relevant persons.

**Hong Kong:** J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong, and J.P. Morgan Broking (Hong Kong) Limited (CE number AAB027) is regulated by the Securities and Futures Commission in Hong Kong. JP Morgan Chase Bank, N.A., Hong Kong Branch (CE Number AAL996) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission, is organized under the laws of the United States with limited liability. Where the distribution of this material is a regulated activity in Hong Kong, the material is distributed in Hong Kong by or through J.P. Morgan Securities (Asia Pacific) Limited and/or J.P. Morgan Broking (Hong Kong) Limited.

**India:** J.P. Morgan India Private Limited (Corporate Identity Number - U67120MH1992FTC068724), having its registered office at J.P. Morgan Tower, Off. C.S.T. Road, Kalina, Santacruz - East, Mumbai – 400098, is registered with the Securities and Exchange Board of India (SEBI) as a ‘Research Analyst’ having registration number INH000001873. J.P. Morgan India Private Limited is also registered with SEBI as a member of the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited (SEBI Registration Number – INZ000239730) and as a Merchant Banker (SEBI Registration Number - MB/INM000002970). Telephone: 91-22-6157 3000, Facsimile: 91-22-6157 3990 and Website: <http://www.jpmpi.com>. JPMorgan Chase Bank, N.A. - Mumbai Branch is licensed by the Reserve Bank of India (RBI) (Licence No. 53/ Licence No. BY.4/94; SEBI - IN/CUS/014/ CDSL : IN-DP-CDSL-444-2008/ IN-DP-NSDL-285-2008/ INBI00000984/ INE231311239) as a Scheduled Commercial Bank in India, which is its primary license allowing it to carry on Banking business in India and other activities, which a Bank branch in India are permitted to undertake. For non-local research material, this material is not distributed in India by J.P. Morgan India Private Limited. Compliance Officer: Pranav Sata; [pranav.d.sata@jpmchase.com](mailto:pranav.d.sata@jpmchase.com); +912261573209. Grievance Officer: Ramprasad K, [jpmpi.research.feedback@jpmorgan.com](mailto:jpmpi.research.feedback@jpmorgan.com); +912261573000. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Please visit [Terms and Conditions and Most Important Terms and Conditions \(MITC\)](#). The annual Compliance audit report is available at <http://www.jpmpi.com/#research>.

**Indonesia:** PT J.P. Morgan Sekuritas Indonesia is a member of the Indonesia Stock Exchange and is registered and supervised by the Otoritas Jasa Keuangan (OJK).

**Korea:** J.P. Morgan Securities (Far East) Limited, Seoul Branch, is a member of the Korea Exchange (KRX). JPMorgan Chase Bank, N.A., Seoul Branch, is licensed as a branch office of foreign bank (JPMorgan Chase Bank, N.A.) in Korea. Both entities are regulated by the Financial Services Commission (FSC) and the Financial Supervisory Service (FSS). For non-macro research material, the material is distributed in Korea by or through J.P. Morgan Securities (Far East) Limited, Seoul Branch.

**Japan:** JPMorgan Securities Japan Co., Ltd. and JPMorgan Chase Bank, N.A., Tokyo Branch are regulated by the Financial Services Agency in Japan.

**Malaysia:** This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X), which is a Participating Organization of Bursa Malaysia Berhad and holds a Capital Markets Services License issued by the Securities Commission in Malaysia.

**Mexico:** J.P. Morgan Casa de Bolsa, S.A. de C.V. and J.P. Morgan Grupo Financiero are members of the Mexican Stock Exchange and are authorized to act as a broker dealer by the National Banking and Securities Exchange Commission.

**New Zealand:** This material is issued and distributed by JPMSAL in New Zealand only to "wholesale clients" (as defined in the Financial Markets Conduct Act 2013). JPMSAL is registered as a Financial Service Provider under the Financial Service providers (Registration and Dispute Resolution) Act of 2008.

**Philippines:** J.P. Morgan Securities Philippines Inc. is a Trading Participant of the Philippine Stock Exchange and a member of the Securities Clearing Corporation of the Philippines and the Securities Investor Protection Fund. It is regulated by the Securities and Exchange Commission.

**Singapore:** This material is issued and distributed in Singapore by or through J.P. Morgan Securities Singapore Private Limited (JPMS) [MDDI (P) 057/08/2025 and Co. Reg. No.: 199405335R], which is a member of the Singapore Exchange Securities Trading Limited, and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore), both of which are regulated by the Monetary Authority of Singapore. This material is issued and distributed in Singapore only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289 (SFA). This material is not intended to be issued or distributed to any retail investors or any other investors that do not fall into the classes of "accredited investors," "expert investors" or "institutional investors," as defined under Section 4A of the SFA. Recipients of this material in Singapore are to contact JPMS or JPMCB Singapore in respect of any matters arising from, or in connection with, the material.

**South Africa:** J.P. Morgan Equities South Africa Proprietary Limited and JPMorgan Chase Bank, N.A., Johannesburg Branch are members of the Johannesburg Securities Exchange and are regulated by the Financial Services Conduct Authority (FSCA).

**Taiwan:** J.P. Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. Material relating to equity securities is issued and distributed in Taiwan by J.P. Morgan Securities (Taiwan) Limited, subject to the license scope and the applicable laws and the regulations in Taiwan. **To the extent that J.P. Morgan Securities (Taiwan) Limited produces research materials on securities not listed on the Taiwan Stock Exchange or Taipei Exchange ("Non-Taiwan Listed Securities"), these materials shall not constitute securities recommendations for the purpose of applicable Taiwan regulations, and, for the avoidance of doubt, J.P. Morgan Securities (Taiwan) Limited does not act as broker for Non-Taiwan Listed Securities.** According to Paragraph 2, Article 7-1 of Operational Regulations Governing Securities Firms Recommending Trades in Securities to Customers (as amended or supplemented) and/or other applicable laws or regulations, please note that the recipient of this material is not permitted to engage in any activities in connection with the material that may give rise to conflicts of interests, unless otherwise disclosed in the "Important Disclosures" in this material.

**Thailand:** This material is issued and distributed in Thailand by JPMorgan Securities (Thailand) Ltd., which is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission, and its registered address is 3rd Floor, 20 North Sathorn Road, Silom, Bangrak, Bangkok 10500.

**UK:** Research is produced in the UK by J.P. Morgan Securities plc ("JPMS plc") which is a member of the London Stock Exchange and is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority or J.P. Morgan Markets Limited ("JPML Ltd") which is authorised and regulated by the Financial Conduct Authority. Unless specified to the contrary, this material is distributed in the UK by JPMS plc and is directed in the UK only to: (a) persons having professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) (Order) 2005 ("the FPO"); (b) persons outlined in article 49 of the FPO (high net worth companies, unincorporated associations or partnerships, the trustees of high value trusts, etc.); or (c) any persons to whom this communication may otherwise lawfully be made; all such persons being referred to as "UK relevant persons". This material must not be acted on or relied on by persons who are not UK relevant persons. Any investment or investment activity to which this material relates is only available to UK relevant persons and will be engaged in only with UK relevant persons. A description of J.P. Morgan EMEA's policy for prevention and avoidance of conflicts of interest related to the production of Research can be found at the following link: [J.P. Morgan EMEA - Research Independence Policy](#).

**U.S.:** J.P. Morgan Securities LLC ("JPMS") is a member of the NYSE, FINRA, SIPC, and the NFA. JPMorgan Chase Bank, N.A. is a member of the FDIC. Material published by non-U.S. affiliates is distributed in the U.S. by JPMS who accepts responsibility for its content.

**General:** Additional information is available upon request. The information in this material has been obtained from sources believed to be reliable. While all reasonable care has been taken to ensure that the facts stated in this material are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable, JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) make no representations or warranties whatsoever to the completeness or accuracy of the material provided, except with respect to any disclosures



relative to J.P. Morgan and the Research Analyst's involvement with the issuer that is the subject of the material. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this material. There may be certain discrepancies with data and/or limited content in this material as a result of calculations, adjustments, translations to different languages, and/or local regulatory restrictions, as applicable. These discrepancies should not impact the overall investment analysis, views and/or recommendations of the subject company(ies) that may be discussed in the material. Artificial intelligence tools may have been used in the preparation of this material, including assisting in data analysis, pattern recognition, and content drafting for research material. J.P. Morgan accepts no liability whatsoever for any loss arising from any use of this material or its contents, and neither J.P. Morgan nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof, apart from the liabilities and responsibilities that may be imposed on them by the relevant regulatory authority in the jurisdiction in question, or the regulatory regime thereunder. Opinions, forecasts or projections contained in this material represent J.P. Morgan's current opinions or judgment as of the date of the material only and are therefore subject to change without notice. Periodic updates may be provided on companies/industries based on company-specific developments or announcements, market conditions or any other publicly available information. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections, which represent only one possible outcome. Furthermore, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified, and future actual results or events could differ materially. The value of, or income from, any investments referred to in this material may fluctuate and/or be affected by changes in exchange rates. All pricing is indicative as of the close of market for the securities discussed, unless otherwise stated. Past performance is not indicative of future results. Accordingly, investors may receive back less than originally invested. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. This material may include views on structured securities, options, futures and other derivatives. These are complex instruments, may involve a high degree of risk and may be appropriate investments only for sophisticated investors who are capable of understanding and assuming the risks involved. The recipients of this material must make their own independent decisions regarding any securities or financial instruments mentioned herein and should seek advice from such independent financial, legal, tax or other adviser as they deem necessary. J.P. Morgan may trade as a principal on the basis of the Research Analysts' views and research, and it may also engage in transactions for its own account or for its clients' accounts in a manner inconsistent with the views taken in this material, and J.P. Morgan is under no obligation to ensure that such other communication is brought to the attention of any recipient of this material. Others within J.P. Morgan, including Strategists, Sales staff and other Research Analysts, may take views that are inconsistent with those taken in this material. Employees of J.P. Morgan not involved in the preparation of this material may have investments in the securities (or derivatives of such securities) mentioned in this material and may trade them in ways different from those discussed in this material. This material is not an advertisement for or marketing of any issuer, its products or services, or its securities in any jurisdiction.

**Confidentiality and Security Notice:** This transmission may contain information that is privileged, confidential, legally privileged, and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained herein (including any reliance thereon) is STRICTLY PROHIBITED. Although this transmission and any attachments are believed to be free of any virus or other defect that might affect any computer system into which it is received and opened, it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by JPMorgan Chase & Co., its subsidiaries and affiliates, as applicable, for any loss or damage arising in any way from its use. If you received this transmission in error, please immediately contact the sender and destroy the material in its entirety, whether in electronic or hard copy format. This message is subject to electronic monitoring: <https://www.jpmorgan.com/disclosures/email>

**MSCI:** Certain information herein ("Information") is reproduced by permission of MSCI Inc., its affiliates and information providers ("MSCI") ©2025. No reproduction or dissemination of the Information is permitted without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES (INCLUDING MERCHANTABILITY OR FITNESS) AS TO THE INFORMATION AND DISCLAIMS ALL LIABILITY TO THE EXTENT PERMITTED BY LAW. No Information constitutes investment advice, except for any applicable Information from MSCI ESG Research. Subject also to [msci.com/disclaimer](https://www.msci.com/disclaimer)

**Sustainalytics:** Certain information, data, analyses and opinions contained herein are reproduced by permission of Sustainalytics and: (1) includes the proprietary information of Sustainalytics; (2) may not be copied or redistributed except as specifically authorized; (3) do not constitute investment advice nor an endorsement of any product or project; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Sustainalytics is not responsible for any trading decisions, damages or other losses related to it or its use. The use of the data is subject to conditions available at <https://www.sustainalytics.com/legal-disclaimers>. ©2025 Sustainalytics. All Rights Reserved.

"Other Disclosures" last revised November 08, 2025.

**Copyright 2025 JPMorgan Chase & Co. All rights reserved. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. It is strictly prohibited to use or share without prior written consent from J.P. Morgan any research material received from J.P. Morgan or an authorized third-party ("J.P. Morgan Data") in any third-party artificial intelligence ("AI") systems or models when such J.P. Morgan Data is accessible by a third-party. It is permissible to use J.P. Morgan Data for internal business purposes only in an AI system or model that protects the confidentiality of J.P. Morgan Data so as to prevent any and all access to or use of such J.P. Morgan Data by any third-party.**

Completed 04 Dec 2025 02:38 PM GMT

Disseminated 05 Dec 2025 12:15 AM GMT